Evidence map›Paper›PMID 34578988›Full record

ArticleNutrients2021

Effects of Elaidic Acid on HDL Cholesterol Uptake Capacity.

Takuya Iino, Ryuji Toh, Manabu Nagao, Masakazu Shinohara, Amane Harada, Katsuhiro Murakami, Yasuhiro Irino, Makoto Nishimori, Sachiko Yoshikawa, Yutaro Seto and 2 more

Open access · goldAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Fish-Derived Omega-3 Fatty Acids: Guardians of High-Density Lipoprotein?Journal of atherosclerosis and thrombosis · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Takuya IinoDivision of Cardiovascular Medicine, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.
Ryuji TohDivision of Evidence-Based Laboratory Medicine, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.
Manabu NagaoDivision of Evidence-Based Laboratory Medicine, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.
Masakazu ShinoharaDivision of Epidemiology, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.
Amane HaradaCentral Research Laboratories, Sysmex Corporation, 4-4-4 Takatsukadai, Nishi-ku, Kobe 651-2271, Japan.
Katsuhiro MurakamiCentral Research Laboratories, Sysmex Corporation, 4-4-4 Takatsukadai, Nishi-ku, Kobe 651-2271, Japan.
Yasuhiro IrinoCentral Research Laboratories, Sysmex Corporation, 4-4-4 Takatsukadai, Nishi-ku, Kobe 651-2271, Japan.
Makoto NishimoriDivision of Cardiovascular Medicine, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.
Sachiko YoshikawaDivision of Cardiovascular Medicine, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.
Yutaro SetoDivision of Cardiovascular Medicine, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.
Tatsuro IshidaDivision of Cardiovascular Medicine, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.
Ken-Ichi HirataDivision of Cardiovascular Medicine, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan.
Kobe University · JPSysmex (Japan) · JP

Funding

the Ministry of Education, Culture, Sports, Science and Technology of Japan 19K08490the Ministry of Education, Culture, Sports, Science and Technology of Japan 20K17081
6 · The paper itself

Abstract

Recently we established a cell-free assay to evaluate "cholesterol uptake capacity (CUC)" as a novel concept for high-density lipoprotein (HDL) functionality and demonstrated the feasibility of CUC for coronary risk stratification, although its regulatory mechanism remains unclear. HDL fluidity affects cholesterol efflux, and trans fatty acids (TFA) reduce lipid membrane fluidity when incorporated into phospholipids (PL). This study aimed to clarify the effect of TFA in HDL-PL on CUC. Serum was collected from 264 patients after coronary angiography or percutaneous coronary intervention to measure CUC and elaidic acid levels in HDL-PL, and in vitro analysis using reconstituted HDL (rHDL) was used to determine the HDL-PL mechanism affecting CUC. CUC was positively associated with HDL-PL levels but negatively associated with the proportion of elaidic acid in HDL-PL (elaidic acid in HDL-PL/HDL-PL ratio). Increased elaidic acid-phosphatidylcholine (PC) content in rHDL exhibited no change in particle size or CUC compared to rHDL containing oleic acid in PC. Recombinant human lecithin-cholesterol acyltransferase (LCAT) enhanced CUC, and LCAT-dependent enhancement of CUC and LCAT-dependent cholesterol esterification were suppressed in rHDL containing elaidic acid in PC. Therefore, CUC is affected by HDL-PL concentration, HDL-PL acyl group composition, and LCAT-dependent cholesterol esterification. Elaidic acid precipitated an inhibition of cholesterol uptake and maturation of HDL; therefore, modulation of HDL-PL acyl groups could improve CUC.

Indexed as

AgedBiological TransportBiomarkersCardiovascular DiseasesCholesterol, HDLFemaleHumansMaleMembrane LipidsOleic AcidsPhosphatidylcholinesPhosphatidylcholine-Sterol O-AcyltransferasePhospholipidsRegistriesTrans Fatty AcidsBiomarkersCholesterol, HDLelaidic acidLCAT protein, humanMembrane LipidsOleic AcidsPhosphatidylcholinesPhosphatidylcholine-Sterol O-AcyltransferasePhospholipidsTrans Fatty Acidscholesterol uptake capacity (CUC)elaidic acidhigh-density lipoprotein (HDL)lecithin-cholesterol acyltransferase (LCAT)phospholipids (PL)trans-fatty acids (TFA)

Identifiers

PMID34578988
PMCPMC8464738
OpenAlexW3198571123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.